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Summary. One hundred and twenty seven consecutive and previously untreated
patients with Hodgkin's disease (HD) (mean age 47 years) from the Stockholm area
admitted to Radiumhemmet, Karolinska Hospital, were studied. The age-matched
control group consisted of167healthy adults. Incorporation of[14C]-dT was measured
on Day 1 in unstimulated monocyte-depleted lymphocyte cultures, and on Day 3 in
cultures activated by PWM, ConA and PPD. T and B cells were enumerated by
surface makers. The patients had significantly decreased relative and total T-cell
counts, and the lymphocyte DNA synthesis Induced by mitogens and PPD was
severely Impaired, whilst the spontaneous DNA synthesis was significantly greater
than in controls. At follow-up (mean4 years) 40 patients have died. Deceased patients
showed greater spontaneous lymphocyte activation and less response to mitogen and
antigen stimulation than the survivors. The 5-year survival of patients with severe
lymphocyte impairment was 20%, compared to 80% for the remainder. The
lymphocyte tests added prognostic information to that from clinical staging.
Disregarding the lack of knowledge of the mechanisms underlying the lymphocyte
impairment, we suggest that these relatively simple immunological tests should
be included in the clinical evaluation of HD patients and would guide the choice
oftherapy.
THE CURRENT REGIMENS of therapy for and impaired host defences against certain
HD have produced a major decrease in the infections (Goffinett etal., 1972; Weitzman
overall death rate, with long-term relapse- & Aisenberg, 1977; Askergren & Bjork-
free survival and cure in the vast majority holm, 1980) have been noted. By better
of young (< 45 years) patients with early- identification of "goodprognosis" patients
stage disease (Kaplan, 1980a). However, one might be able to reduce the total
some young and many elderly patients do amount ofradio- and chemotherapy with-
not enter complete remission, or relapse out losing the therapeutic effectiveness.
shortly after termination of therapy. In the search for new tools to classify
Hence, one important task is still to HD patients, attention has been paid to
identify patients at risk, leading to a more the immunodeficiency which is common in
efficient primary treatment. untreated patients. Thus, delayed cutan-
Alongwiththesuccessfultreatmentwith eous hypersensitivity to recall antigens
intensive radio- and chemotherapy, have (Chase, 1966; Young et al., 1972; Holm
come reports of late complications. An et al., 1976) and to sensitizing agents
increased risk of acute myelocytic leu- such as dinitrochlorobenzene (Aisenberg,
kaemia (Bonadonna et al., 1973; Canellos 1962; Brown et al., 1967; Eltringham &
et al., 1975; Brody & Schottenfeld, 1980) Kaplan, 1973) is depressed, and skin
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allograft survival is prolonged (Green &
Corso, 1958; Kelly et al., 1958; Miller et
al., 1961). It is also generally agreed that
the in vitro T-lymphocyte proliferative
response to phyto-hemagglutinin (PHA),
concanavalin A (ConA), pokeweed mitogen
(PWM) and allogeneic lymphocytes, is
low both in untreated patients and in
patients during remission (Aisenberg,
1965; Hersh & Oppenheim, 1965; Holm
et al., 1967; Bjorkholm, 1978).
In 1973 a prospective study was started
to classify consecutive patients according
to their pretreatment lymphocyte func-
tions. In preliminary reports which were
based on short-term follow-up of a small
number of patients, the lymphocyte
functions seemed to add prognostic infor-
mation to that achieved by age, clinical
stage and histopathology (Bjorkholm et
al., 1975, 1978a). In this study of 127
patients we report a close association
between the pretreatment spontaneous
and mitogen-induced DNA synthesis and
prognosis, whilst other immunological
variables gave no prognostic information.
These immunological functions yielded
prognostic information which was partly
independent of that obtained by clinical
staging, age and histopathology.
CLINICAL MATERIAL AND METHODS
Patients.-The study includes 127 patients
with untreated HD admitted to Radium-
hemmet, Karolinska Hospital andtheDepart-
ment of Medicine, Seraphimer Hospital.
Almost without exception, patients with HD
in the Stockholm area (,I10 million inhabi-
tants) were at that time treated at these two
institutions. Consecutive patients were col-
lected over a 5-year period. There were 81
men and 46 women, with a mean age of 46
years (range 15-88). The age distribution was
characteristically bimodal. The mean dura-
tion of follow-up was 48 months.
All patients had a histological diagnosis
of HD. In 3 the disease was established by
cytological examination of fine-needle aspir-
ates. The histopathology was subclassified
according to the Rye nomenclature (Lukes et
al., 1966). Apart from a detailed history and
a thorough physical examination, all patients
had a complete blood count, erythrocyte
sedimentation rate (ESR), liver enzymes,
serum electrophoresis, marrow aspirations
and biopsies as part oftheirinitial evaluation.
Radiological investigations included chest
roentgenogram, plain abdominal X-ray, liver
and spleen scans and (in a few patients)
computerized tomographic scanning of the
thorax and/or abdomen. All patients except a
few over 80 years of age underwent lower-
extremity lymphangiography. The Ann Arbor
nomenclature for clinical staging was used
(Carbone et al., 1971). The clinical character-
istics of the patients are summarized in
Table I. Fourteen patients with right-sided
nodular sclerosis or lymphocyte-predomin-
ance HD stages I-II A received irradiation
according to the mantle or inverted Y-field
techniques. All Stage IV and 7 Stage III B
patients were given MOPP chemotherapy.
The remaining patients were treated with
total nodal irradiation excluding the hepatic
and splenic areas. Patients in this treatment
group without clinical evidence of splenic
involvement were included in a randomized
study to evaluate the therapeutic effect of
exploratory laparotomy with splenectomy
(Askergren et at., 1980). Twenty-one patients
were randomized to splenectomy and 8
TABLE I.-Distribution ofpatients according to clinical stage, histopathology
and symptoms
Clinical stage
I II III IV
Histopathology A B A B A B A B Total
LP 8 1 4 0 3 4 0 1 21
NS 11 1 11 8 4 10 1 3 49
MC 6 0 6 1 8 7 5 10 43
LD 3 1 0 1 1 1 0 4 11
Unclassified 1 0 0 1 0 1 0 0 3
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patients were splenectomized because of
initial splenomegaly.
Controls.-The age-matched control group
consisted of 167 adults, 101 males and 66
females. Their mean age was 43 years (range
19-91). The large majority were healthy
members ofthe laboratory and hospital staffs
and some of their relatives. Among indivi-
duals over 50 years patients with uncompli-
cated cerebro- or cardiovascular diseases but
without other concomitant diseases were
included. At the time of the test all subjects
had no signs of infectious disease and had a
normal ESR. Drugs were withdrawn 24 h
before lymphocyte studies. For detailed
information, see Wedelin et al. (1982).
Immunological Studies
Lymphocyte purification.-The total num-
ber oflymphocytes was counted. Defibrinated
venous blood was mixed with gelatin and
allowed to sediment. The leucocyte-rich
supernatant was incubated with carbonyl
iron, and phagocytic cells were removed with
a magnet. For determination of lymphocyte
subpopulations, the remaining red blood cells
were removed by sedimentation through a
Ficoll-Isopaque gradient. T lymphocytes are
defined as E+ cells forming spontaneous
rosettes with sheep red blood cells (Jondal et
al., 1972). For further details, see Holm et al.
(1976).
Lymphocyte DNA synthesis.-Lymphocytes
were suspended in RPMI medium (Biocult
Laboratories Ltd, Glasgow) with antibiotics
and 15% pooled and heat-inactivated (56TC,
1 h) human AB serum. In the first part ofthe
study 5 x 105 cells in a total volume of 1-5 ml
were added to conical tubes with or without
stimulants. Later, 105 cells in 0-15 ml were
pipetted to each well of microplates (Flow
Laboratories, Irvine, Ayrshire). The cells were
incubated in humid air with 5% CO2 at 37°C.
In the macro-method, 0.1 ,uCi of [14C-2]-dT
(sp. act. 60 or 10 mCi/mmol; Radiochemical
Centre, Amersham) was added and DNA was
extracted with trichloroacetic acid. In the
micro-method, 25 nCi (sp. act. 60 mCi/mmol)
was added to each well. A Titertee cell
harvester (Flow Laboratories) was used for
microplates. The radio-activity was measured
in a Packard liquid scintillation counter and
the mean ct/min oftriplicate incubations was
calculated. The spontaneous incorporation of
[14C]-dT was measured during the first 24 h
of culture. The dT uptake induced by mito-
gens or antigens was evaluated during the
last 24 h of a 3-day culture. Lymphocytes
from one control was included in each test.
In order to pool the results an index (I) was
established. For this purpose DNA synthesis
of blood lymphocytes was determined by the
various methods in 30 healthy 20-35 year old
donors (Bjorkholm et al., 1981).
- log experimental ct/min
mean log ct/min of controls
The reproducibility was also good when
subjects were tested repeatedly over 2-7
years (Wedelin et at., 1982). As the means and
statistical variations of the indices were the
same as revealed by the F-test the results
were pooled.
Reagents.-PWM was purchased from
Gibco, Berkeley, Cal., U.S.A. and ConA from
Pharmacia Fine Chemicals AB, Upsala,
Sweden. Two batches of each mitogen were
used during the study. Each new batch was
compared with the old one, using normal
lymphocytes in a dose-response experiment
to assure identical ability to activate lym-
phocytes. One batch of purified protein deri-
vative (PPD; State Serum Institute, Copen-
hagen, Denmark) was used throughout the
study.
Delayed cutaneous hypersensitivity.-The
patients received an intradermal injection of
0.1 ml of PPD (2 TU) on the volar surface
of the forearm. The reaction was evaluated
after 48 h. The crossed diameters of the
induration were measured. A mean diameter
of 6 mm or more was considered positive.
Lymphocytes were always collected for in
vitro studies beforethe skin test.
Statistics
The significance of differences between mean
values was tested by the t test. As a measure
of association between variables, Pearson's
product-moment correlation (r) was chosen.
Differences between relative numbers were
tested by the X2 test. Survival curves were
calculated according to the product-limit
estimator (Kaplan & Meier, 1958) and differ-
ences in survival were evaluated by the
Kolmogorov-Smirnov test for censored sur-
vival times (Breslow & Crowley, 1974). The
relative prognostic importance of variables
were analysed using the life-table regression
model (Cox, 1972).
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RESULTS
Total lymphocyte and E+ lymphocyte
counts, as well as the percentage of E+
cells, were significantly decreased in the
patients (Table II). No correlation be-
tween age and total lymphocyte and E+
cell counts was seen in the patient group.
However, in the controls total and relative
E+ lymphocyte counts decreased with age
(r= -0 17; P<0-05; r= -0-22; P<0-01,
respectively). Total lymphocyte counts
but not E+ cell counts were significantly
lower in patients with constitutional
symptoms (Table III). No influence ofthe
clinical stage on lymphocyte counts was
found.
The lymphocyte response to PWM,
ConA and PPD was markedly decreased
and the spontaneous DNA synthesis was
significantly increased in the patient
group (Table II). ConA-induced DNA
synthesis declined with age in the patients
(r= -0 53; P<0 001) as did the response
to PWM (r= -0 33; P<0 001) but not to
PPD (r= -0-16). Lymphocyte stimula-
tion declined with age also in the controls:
ConA (r=-0-46; P<0-001); PWM (10
/-tg/ml) (r= -0-32; P<0-001); PPD (r=
- 025; P< 0.01). The lymphocyte res-
ponse to mitogens and antigen was low
and the spontaneous lymphocyte activity
high, in patients with B symptoms and
advanced disease (Table III).
None of the immunological variables
TABLE II.-Lymphocyte counts and stimulation in patients and controls (mean + s.d.).
All patient valu,es differfrom the control values with P< 0-001
Patients Controls
-- (n=127) (n=167)
Lymphocyte counts
(log No./mm3)
E+ lymphocyte counts
(log No./mm3)
(%)
DNA synthesis
(I-values)
Spontaneous
PWM 1 ,ug/ml
PWM 10 ,sg/ml
Con A 20 ,ug/ml
Con A 40 ,ug/ml
Con A 80 ,ug/ml
PPD 2 - 5 sg/ml
3 08+0 29 3-22+0-20
2 87+0 28 3-04+0-21
61-2+ 12-8 67-3+6-7
1-16+0- 17
0 87+0-16
0-90+0-12
0 88+0-13
0-89+0-13
0 89+ 0-13
0 86+0-16
1 -02 + 0- 15
0-98+ 0-16
0 99+0 07
0 97+0-10
0 96+0-10
0 96+0-12
0-99+0-16
TABLE III.-Lymphocyte counts and stimulation in relation to clinical stage and symptoms
(mean +s.d.)
Clinical staget
I II
(n = 32) (n =32)
III
(n =39)
IV
(n=24)
Total lymphocyte counts
(log No./mm3) 3-12+0-20 3-13+0-26 3 00+0-38 3-06+0-22
Total E+ lymphocyte counts
(log No./mm3) 2-83 +030 2-92+0-31 2-86+0-29 2-84+0-19
DNA synthesis
Spontaneous 1-07+0-15 1-16+ 0.20* 1-20+ 0-14*** 1-22+ 0.24**
PWM 1 ,ug/ml 0-92+0-17 0-92+0-13 0-84+0-16* 0-77+0-13***
ConA 20 /tg/ml 0-89+0-12 0-94+0-13 0-85+0-13 0-84+0-12
PPD 2-5 ,ug/ml 0-94+0-16 0-88+0-11 0-83+0-18** 0-81+0-14**
Symptomst
A
A B
(n= 72) (n=55)
3-13+0-21 3-01+0-35*
2-89+0-27 2-83+ 0-30
1-10+ 0-16 1-25+ 0-19***
0-90+ 0-14 0-82+0-17**
0-89+0-13 0*87+0-13
0-91+0-14 0-81+0-17***
t Significance levels refer to comparison between Stage I and Stages II, III and IV respectively.
$ Significance levels refer to comparison between patients without (A) and with constitutional symptoms
(B).
* P<0 05
**P<0-01
*** P < O- 001
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TABLE IV.-Correlation8 (r) between lymphocyte counts and stimulation
% E+ cells
Total E+ cell counts
Spontaneous
PWM (1 ,tg/ml)
ConA (20 ,ug/ml)
PPD (2 5 ,ug/ml)
*P<0 05 **P<0.01
***P<0-001
Total
lymphocyte
counts
0 26**
0.81***
-0-15
0-11
0-16
-0*04
% E+
cells
0*49***
-0 03
-0-02
0 07
-011
Total
E+ cell
counts
-0-10
0-02
0-16
-0*03
PWM
Spontaneous (1 jug/ml)
-0-17
-0-15
-0.21*
0*53***
0.51***
TABLE V.-PPD reactivity in relation to age and clinical stage
PPD-induced lymphocyte DNA synthesis
(mean I-value +s.d.)
Age (mean years +s.d.)
Clinical stage (No.)
I-II
III-IV
Symptoms (No.)
A
B
PPD skin positive
(n=33)
0-94+0-15
48-9+ 158
24
9
22
11
PPD skin negative
(n= 69)
0 85+0*15
43-5+ 198
30
39
38
31
N.S. =not significant.
TABLE VI.-Lymphocyte counts and stimulation in relation to prognosis (mean + s.d.)
Total lymphocyte counts
(log No./mm3)
Total E+ lymphocyte counts
(log No./mm3)
DNA 8ynthesis
(I-values)
Spontaneous
PWM (1l gfml)
PWM (10 ,ug/ml)
ConA (20 itg/ml)
ConA (40 ,ig/ml)
ConA (80 fig/ml)
PPD (2:
- fg/ml)
N.S. =not significant.
correlated with the histopathological pic-
ture (data not shown).
A positive correlation between the total
number of lymphocytes and total and
relative E+ cell counts was observed in the
patient group (Table IV). The spontan-
eous, mitogen- and antigen-induced lym-
phocyte DNA synthesis did not correlate
with lymphocyte or E+ cell counts. How-
ever, the lymphocyte response to ConA
Living patients
(n = 87)
3-10+0-25
2 85+ 0*31
1-13+0-17
0-90+ 0-16
0-93+0.11
0-91+ 0-13
0 92+ 0-13
0 92+0-14
0 89+0 15
Deceased patients
(n =40)
3 07+0 28
2 89+0-22
1-22+0-15
0-78+0-13
0 85+0-13
0-82+0-11
0-84+0-12
0-84+ 0-10
0-80+0-17
p
N.S.
N.S.
<0*005
<0 005
<0 005
<0-001
<0*005
<0-01
<0 005
and PWM was associated at all tested
concentrations (Table IV). A less pro-
nounced correlation between PPD and
mitogen-induced DNA synthesis was ob-
served. The spontaneous DNA synthesis
showed only a weak inverse correlation
with the PPD response (Table IV). The
PPD-induced DNA synthesis in vitro
followed the delayed cutaneous hyper-
sensitivity to PPD (Table V). The number
Con A
(20 tg/ml)
0 27***
p
<0*005
N.S.
<0-01
N.S.
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ofPPD skin-positive patients was equally
distributed in the different age groups.
PPD anergy was more common in patients
with advanced disease (Table V). How-
ever, there was no association between B
symptoms andPPD skinreactivity.
The pretreatment lymphocyte counts
and functions in relation to death or
survival at follow-up are shown in Table
VI. Patients with a fatal outcome had
poorer lymphocyte responses to mitogen
and antigen stimulation than the remain-
ing patients. Furthermore, the spon-
taneous DNA synthesis was markedly
increased in patients with bad prognosis.
Lymphocyte and E+ counts and PPD
1.5-
0
o
cU
0 a.
1.0-
0
0
0
O
0 0 0 0.
0 *
0e zb * ' Is 0 0
000 o
0
0
* O
0 e
0
0 0
0
0
0
0
a 0
0
0 O
a 0 0
0
0
O cb *0ooM 00% 0A
skin reactivity did not differ between the
two patient groups (Table VI and data not
shown).
The pretreatment spontaneous and
ConA (20 ,g/ml) induced lymphocyte
DNA synthesis of each patient in relation
to prognosis is shown in Fig. 1. Twenty-
six of 40 patients (65%) with increased
spontaneous (approximately control mean
+1 s.d.) and a decreased mitogen-induced
lymphocyte activity (approximately con-
trol mean -1 s.d.) had succumbed, while
only 13 ofremaining 83patients (16%) had
a fatal outcome. Very similar prognostic
discrimination was furnished by PWM,
but not by PPD-induced lymphocyte
stimulation (data not shown).
Cox's life table regression was used to
evaluate the importance of clinical and
immunological variables of prognosis
(Table VII) (Bjorkholm et al., 1979).
Age gave the most information. Clinical
stage was associatedwithprognosis, whilst
histology and symptomatology were not.
- 0
g'e 0 0%0
0O 000 0 fb
0 0
0
0 0
I-
0.5 1.0
Con A - induced
FIG. 1.-Correlation between spontaneous
and ConA (20 ,ug/ml) induced blood-
lymphocyte DNA synthesis (I-value) in
HD (0 =patient alive; 0 =deceased
patient).
2 3
Time (Years)
FIG. 2.-Survival of HD patients with
normal (.... ) and increased (- -)
spontaneous blood-lymphocyte DNA syn-
thesis.
TABLE VII.-Standardized regression coefficients according to Cox's life-table regression
Lymphocyte DNA synthesis
Age Spontaneous ConA20 PWM1
0-44 0 30 -0-26 -0 20
Clinical
stage
0-16
Histopathology
-0-01
75
Symptoms
-0.01
i~~ A.
-
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35%0 of low responders had survived
(P < 0 01; Fig. 3). By combination of two
independent immunological variables (i.e.
spontaneous and ConA-induced DNA syn-
thesis, Table IV) the prognostic value
increased considerably. The 5-yearsurvival
of patients with no impairment was
found to be 80%, which is in sharp con-
trast to a 20% survival rate ofthe remain-
ing patients (P< 0 01; Fig. 4).
DISCUSSION
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Time (Yea rs) in blood and mitogen- and antigen-
3 il o (years) induced lymphocyte DNA synthesis were
3. Sulrvival of HD patients wTithl nor-. . nal ( ) and decreased ( ) ConA lower in patients than in age-matched
20 ,ug/ml) induced blood-lymphocyte DNA controls, whilst the spontaneous DNA
ynthesis. synthesis was increased in patients, thus
confirming previous reports (Levy &
Kaplan, 1974; Holm et al., 1976). While
the mitogen response (ConA in particular)
declined with age, both in patients and
controls, the spontaneous lymphocyte
activity was not age-dependent (Girard et
al., 1977; Wedelin et al., 1982). No associ-
ation between these lymphoctye functions
...... and histopathology was noted. However,
deviation from normal of spontaneous,
........... PWM- and PPD-induced DNA synthesis
..........
....... was more marked in patients with ad-
vanced disease or B symptoms. Hence, one
might argue that the prognostic informa-
) 1 2 3 4 5 6 tion given by certain lymphocyte tests
me (year) 6may depend upon conventional clinical
Ti4.mSurviva of yRD patits w predictors of prognosis in a complex way .4.-Survival of HD patients wit-h an X Bokome a., 197a 198 Kpa icreased spontaneous and1 decreased ConA (BjOrkholm et al., 1977a, 1978a; Kaplan
20 ,ug/ml) induced blood-lymphocyte DNA 1980b). Such an alternative can be tested
ynthesis
.--;n 40) and of remaining by comparing the clinical characteristics
and lymphocyte functions of deceased
patients with those of surviving patients.
itaneous, ConA- and PWM-induced By grouping the patients according to
synthesis as single factors gave their spontaneous and ConA (or PWM)-
prognostic information than clinical induced lymphocyte DNA synthesis, a
but less to that given by age. 65% mortality was observed in patients
ie 5-year survival rate ofpatients with with severe impairment as opposed to 160%
rmal spontaneous lymphocyte activity mortality in immunologically "normal"
80%, compared with 450o for the patients. Thus, the combined effect of
lining patients (P < 0 01; Fig. 2). 7500 these two, independent variables is more
Le patients with a normal lymphocyte indicative of poor prognosis than any
V response lived at 5 years, whilst only other known factor. The importance of
100
1-
Cu
> 50
v)
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this finding is further underlined by the
survival in relation to lymphocyte capa-
city. The results of the present study
greatly extend and confirm our prelimin-
ary findings which were based on smaller
patient materials for shorter observation
times (Bjorkholm et al., 1975, 1978a). The
results clearly demonstrate that the pre-
treatment blood-lymphocyte functions
measured as spontaneous and mitogen
(ConA and PWM)-induced DNA synthesis
constitute powerful predictors ofprognosis
in HD.
Cell-mediated immunity is selectively
impaired in virtually all untreated patients
with HD (for references see Bjorkholm,
1978; Twomey & Rice, 1980). The
severity of the immunodeficiency may
vary and is not necessarily related to the
extent of the disease (Levy & Kaplan,
1974; Bjorkholm et al., 1978a). During the
last 15 years many studies have been
focused on the nature of the immune
defect, yet, the mechanisms underlying
the immunological dysfunction are only
partly exposed. Some facets of the immu-
nodeficiency seem to be associated with
active disease. Thus, the lymphocyte
stimulation by recall antigen in vitro and
in vivo, and to some extent the spontan-
eous lymphocyte DNA synthesis, may
eventually normalize (Sokal & Primikirios,
1961; King et al., 1976; Gobbi et al., 1977;
Bjorkholm et al., 1977b, c, 1981). Lympho-
cyte inhibitory serum factors which dis-
appear after successful treatment may
contribute to the deficiency during active
disease (Holm et al., 1979a, b). On the
other hand, impairment of T-lymphocyte
stimulation by mitogen seems to persist
in cured patients (Bjorkholm et al.,
1977b, c, 1981; Case et al., 1977). A similar
lymphocyte deficiency has also been
described in healthy consanguineous and
non-consanguineous relatives of HD
patients (Bjorkholm et al., 1977d; 1978b).
Autoantibodies to lymphocyte subsets
may play a role by lysis or opsonization
leading to trapping and destruction in the
spleen (Bjorkholm, 1978; De Sousa et al.,
1978; Holm et al., 1979b; Bjorkholm et al.,
1980). This hypothesis has gained some
support from studies of the role of the
spleen in HD. Thus, in patients with
tumour-engaged spleens an inverse rela-
tionship between spleen size and the
lymphocyte response to PWM stimulation
has been reported (Bjorkholm et al., 1980).
Moreover, mitogen-reactive lymphocytes
are also present in the spleen in patients
with severe blood-lymphocyte defects
(Twomey et al., 1976; Willson et al., 1977).
Imbalance in regulation by macrophages
or T cells may also contribute (Twomey et
al., 1975; Goodwin et al., 1977) but has not
been confirmed (Holm et al., 1981). Dis-
regarding its mechanisms, the degree of
immunological malfunction before institu-
tion oftherapy may mirrorin an unspecific
way the patient's ability to cope with his
disease.
One can only speculate on the reason
for the association between lymphocyte
function and prognosis. A likely explana-
tion would be that T-lymphocytes partici-
pate in the tumour defence. Destruction,
inactivation or elimination ofsuch cells by
the spleen or by other tissues may lead to
inefficient tumour defence. However, T-
cells may have no bearing on tumour
resistance. Rather, the persistent T-
lymphocyte malfunction in HD may
reflect the influence ofsome external factor
(virus?), preexisting or acquired as a
consequence of the tumour (Bjorkholm,
1978; Holm et al., 1979b). In this case, the
severity of the defect may rather mirror
the aggressiveness ofthe tumour.
Notwithstanding the lack of knowledge
on the relationship between the lympho-
cyte abnormalities and the disease process,
we believe that lymphocyte testing may
be an important tool in the clinical pre-
treatment evaluation to give a better basis
for choice oftherapy in HD. A prospective
study has therefore been started, where
patients are allocated to different treat-
ment regimens according to their pre-
treatment; lymphocyte functions.
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